BioNexus Gene Lab Corp Common stock
Compare this stock
BGLC Stock Report Card
$
31%
Performance
Score:
10/100
BGLC returned -97.12% in the last 12 months. Based on SPY's performance of -13.73%, its performance is below average giving it a score of 10 of 100.
Profit
Score:
33/100
Out of the last 18 quarters, BGLC has had 6 profitable quarters and has increased their profits year over year on 4 of them.
Volatility
Score:
56/100
BGLC has had a higher than average amount of volatility over the last 12 months giving it a score of 56 of 100.
BioNexus Gene Lab Corp Common stock Summary
Nasdaq / BGLC
Healthcare
Medical - Diagnostics & Research
BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
BGLC scored poorly on our reportcard. Here are some similar companies and how they performed.
